This study is testing if giving two medications, called **ipilimumab** and **nivolumab**, at different times of the day can help treat advanced **melanoma**, a serious type of skin cancer. These medications are a type of **immunotherapy** that helps the body's defense system fight cancer. The study wants to see if taking these medicines in the morning is better than taking them at other times. - **Participation Length**: The treatment lasts up to 2 years, with follow-ups every 3 months for a year, then up to 5 years. - **Study Visits**: You'll need to visit regularly for infusions and tests, which include scans and possibly biopsies. - **Risks and Benefits**: You might experience side effects, but this study could help find better treatment timings for melanoma. You can join if you have stage IV melanoma, and haven't had immunotherapy in the last year. Your organs should be in good shape, but you can't join if you have certain other health conditions. Participants will be randomly assigned to one of three groups, each receiving the medications at different times. This study may help improve treatment outcomes for melanoma patients.